| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/ART.10758 |
| P8608 | Fatcat ID | release_tdooamltgrerbp6i6dyf52tzoe |
| P698 | PubMed publication ID | 12571839 |
| P2093 | author name string | Jong-Hoon Lee | |
| M Miles Braun | |||
| Sharon K Gershon | |||
| Evelyne T Edwards | |||
| Nancy R Slifman | |||
| P433 | issue | 2 | |
| P921 | main subject | Listeria monocytogenes | Q292015 |
| P304 | page(s) | 319-324 | |
| P577 | publication date | 2003-02-01 | |
| P1433 | published in | Arthritis & Rheumatology | Q4797636 |
| P1476 | title | Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents | |
| P478 | volume | 48 |
| Q95359387 | Q95359387 |
| Q95359600 | Q95359600 |
| Q28282330 | A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab |
| Q37814549 | A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease. |
| Q43282843 | A life-threatening abscess in a patient treated with a tumour necrosis factor-alpha antagonist: a case report |
| Q35040269 | ADAM17-mediated processing of TNF-α expressed by antiviral effector CD8+ T cells is required for severe T-cell-mediated lung injury |
| Q35637012 | ASAS/EULAR recommendations for the management of ankylosing spondylitis |
| Q45397328 | Active immunization with IL-1 displayed on virus-like particles protects from autoimmune arthritis |
| Q38105072 | Age-dependent differences in systemic and cell-autonomous immunity to L. monocytogenes |
| Q35842626 | Anakinra: an inhibitor of IL-1 for the treatment of rheumatoid arthritis |
| Q24673716 | Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety |
| Q42108205 | Aseptic meningitis in a patient taking etanercept for rheumatoid arthritis: a case report |
| Q33819684 | Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry |
| Q24793159 | Attenuation of inflammatory polyarthritis in TNF transgenic mice by diacerein: comparative analysis with dexamethasone, methotrexate and anti-TNF protocols |
| Q35637343 | Baseline comorbidity levels in biologic and standard DMARD treated patients with rheumatoid arthritis: results from a national patient register |
| Q38192553 | Beyond tumor necrosis factor inhibition: the expanding pipeline of biologic therapies for inflammatory diseases and their associated infectious sequelae |
| Q36780929 | Biologic agents in rheumatology: safety considerations |
| Q38020037 | Biologic therapy in psoriasis: perspectives on associated risks and patient management |
| Q35893172 | Biologics in combination with nonbiologics: efficacy and safety |
| Q35026302 | Cause for controversy? Infliximab in the treatment of ulcerative colitis: an update |
| Q44996519 | Cavitating pneumonia after treatment with infliximab and prednisone |
| Q34250544 | Central but not systemic administration of XPro1595 is therapeutic following moderate spinal cord injury in mice |
| Q36356947 | Change in physiotherapy management of children with cystic fibrosis in a large urban hospital |
| Q35237588 | Choice of Biologic Therapy for Patients with Rheumatoid Arthritis: The Infection Perspective |
| Q33222422 | Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis |
| Q37286284 | Effects of Calcium Gluconate, a Water Soluble Calcium Salt on the Collagen-Induced DBA/1J Mice Rheumatoid Arthritis |
| Q57779961 | Emergence of Legionella pneumophila Pneumonia in Patients Receiving Tumor Necrosis Factor- Antagonists |
| Q35779227 | Etanercept: a clinical review of current and emerging indications |
| Q46556662 | Existing medications among non-pregnancy-related listeriosis patients in England, 2007-2009. |
| Q47915123 | Fatal staphylococcal sepsis in Crohn's disease after infliximab |
| Q81313124 | Fatigue in patients with advanced cancer: a pilot study of an intervention with infliximab |
| Q51850846 | Fragile X-related protein FXR1 controls post-transcriptional suppression of lipopolysaccharide-induced tumour necrosis factor-alpha production by transforming growth factor-beta1. |
| Q38008692 | Histone deacetylase inhibitors as suppressors of bone destruction in inflammatory diseases. |
| Q36944802 | IDO-expressing regulatory dendritic cells in cancer and chronic infection |
| Q50042207 | IFN-Gamma-Dependent and Independent Mechanisms of CD4⁺ Memory T Cell-Mediated Protection from Listeria Infection |
| Q36328708 | Immunosuppression related to collagen-vascular disease or its treatment |
| Q24653374 | Immunotoxicity of monoclonal antibodies |
| Q33845259 | Increased survival after gemfibrozil treatment of severe mouse influenza |
| Q35131219 | Indoleamine 2,3-dioxygenase-expressing dendritic cells form suppurative granulomas following Listeria monocytogenes infection |
| Q38335718 | Infection risk associated with anti-TNF-α agents: a review |
| Q37050242 | Infections and IBD. |
| Q35581950 | Infections and anti–tumor necrosis factor α therapy |
| Q37463702 | Infections in children and adolescents with juvenile idiopathic arthritis and inflammatory bowel disease treated with tumor necrosis factor-α inhibitors: systematic review of the literature |
| Q36154725 | Infectious complications of tumor necrosis factor-alpha antagonists |
| Q33371653 | Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study |
| Q36099482 | Infliximab for the treatment of early rheumatoid arthritis |
| Q35553371 | Lessons learned in the use of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis |
| Q42844757 | Life threatening intra-abdominal sepsis in patients on anti-TNF-alpha therapy. |
| Q38012883 | Listeria infection in patients on anti-TNF treatment: report of two cases and review of the literature |
| Q80501553 | Listeria infections associated with infliximab: case reports |
| Q53905156 | Listeria meningitis associated with infliximab. |
| Q38584500 | Listeria meningitis complicating a patient with ulcerative colitis on concomitant infliximab and hydrocortisone |
| Q36171112 | Listeria meningitis complicating infliximab treatment for Crohn's disease |
| Q37156803 | Listeria monocytogenes: epidemiology, human disease, and mechanisms of brain invasion |
| Q33859169 | Listeria-associated arthritis in a patient undergoing etanercept therapy: case report and review of the literature |
| Q38097376 | Listeriosis in patients receiving biologic therapies |
| Q36331225 | Managing complicated Crohn's disease in children and adolescents |
| Q57470182 | Modulation of T-cell responses by anti-tumor necrosis factor treatments in rheumatoid arthritis: a review |
| Q35216972 | Molecular targets in immune-mediated diseases: the case of tumour necrosis factor and rheumatoid arthritis |
| Q57804288 | Mucosal NOD2 expression and NF-κB activation in pediatric Crohnʼs disease |
| Q61804073 | Nontyphoidal Salmonella purulent pericarditis presenting with pericardial tamponade in a patient on infliximab therapy |
| Q38673326 | Not all TNF inhibitors in rheumatoid arthritis are created equal: important clinical differences |
| Q35164740 | Novel biological immunotherapies for psoriasis |
| Q38139812 | Opportunistic infections due to inflammatory bowel disease therapy |
| Q27319559 | Oral TNFα Modulation Alters Neutrophil Infiltration, Improves Cognition and Diminishes Tau and Amyloid Pathology in the 3xTgAD Mouse Model |
| Q39196558 | Oral infection control to assist infliximab therapy in a Behçet's disease patient with severe eye inflammation in response to dental treatment: a case report |
| Q35838590 | Pathogenesis of malaria and clinically similar conditions |
| Q37776736 | Perioperative management of tumor necrosis factor antagonists in patients with psoriasis and other inflammatory disorders |
| Q36704473 | Plasmid-based gene therapy of diabetes mellitus |
| Q34153073 | Rationale of using different biological therapies in rheumatoid arthritis |
| Q36821981 | Reactivation of latent tuberculosis by TNF blockade: the role of interferon gamma |
| Q28262381 | Regulation of tumour necrosis factor signalling: live or let die |
| Q44278805 | Risk of Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis treated with inhibitors of tumour necrosis factor α: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. |
| Q33315300 | Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials |
| Q55335193 | Role of TNF-TNF Receptor 2 Signal in Regulatory T Cells and Its Therapeutic Implications. |
| Q35553478 | Role of tumour necrosis factor (TNF) in host defence against tuberculosis: implications for immunotherapies targeting TNF |
| Q35194346 | Safety and efficacy of disease-modifying antirheumatic agents in rheumatoid arthritis and juvenile rheumatoid arthritis |
| Q37980484 | Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis |
| Q36548668 | Safety of etanercept in psoriasis: a critical review |
| Q38284560 | Safety of off-label biologicals in systemic lupus erythematosus |
| Q35734045 | Safety of tumour necrosis factor-alpha antagonists |
| Q35705082 | Serious infection during etanercept, infliximab and adalimumab therapy for rheumatoid arthritis: A literature review |
| Q35937819 | Serious infections associated with anticytokine therapies in the rheumatic diseases |
| Q48137954 | Soluble Tumor Necrosis Factor Alpha Promotes Retinal Ganglion Cell Death in Glaucoma via Calcium-Permeable AMPA Receptor Activation |
| Q98224728 | Susceptibility to Intracellular Infections: Contributions of TNF to Immune Defense |
| Q37553588 | The Effects of Platycodin D, a Saponin Purified from Platycodi Radix, on Collagen-Induced DBA/1J Mouse Rheumatoid Arthritis |
| Q38686563 | The alternate effects of anti-TNFα therapeutics and their role in mycobacterial granulomatous infection in Crohn's disease |
| Q35173590 | The occurrence and prevention of foodborne disease in vulnerable people. |
| Q37784863 | The roles of TNF in brain dysfunction and disease |
| Q35919214 | The safety of etanercept for the treatment of plaque psoriasis. |
| Q35859217 | The treatment of rheumatoid arthritis |
| Q35688168 | The use of TNF-alpha blocking agents in rheumatoid arthritis: an overview |
| Q36916918 | The use of TNF-alpha blocking agents in rheumatoid arthritis: an update |
| Q35567825 | Transition from methotrexate and cyclosporine to other therapies including retinoids, ultraviolet light and biologic agents in the management of patients with psoriasis |
| Q53598442 | Transmembrane TNF protects mutant mice against intracellular bacterial infections, chronic inflammation and autoimmunity. |
| Q33213561 | Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept |
| Q46969577 | Treatment with anti-TNF monoclonal antibody (c5N) reduces the extent of induced endometriosis in the baboon |
| Q53668818 | Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept? |
| Q47561672 | Tumor necrosis factor blockers influence macrophage responses to Mycobacterium tuberculosis |
| Q40672157 | Tumour necrosis factor inhibitors and infection: What is there to know for infectious diseases physicians? |
| Q35989499 | Tumour necrosis factor inhibitors: risks and benefits in patients with rheumatoid arthritis |
| Q34620375 | Update of the management of chronic psoriasis: new approaches and emerging treatment options. |
| Q35638252 | Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006. |
| Q36171750 | Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007 |
| Q35553451 | Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003). |
| Q35579352 | Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004. |
| Q35579517 | Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005 |
| Q36588861 | Use of biologics in rheumatoid arthritis: where are we going? |
| Q80526600 | [Arthritis due to Listeria monocytogenes] |
| Q84600169 | [Biologic therapy and infections] |
| Q81395234 | [Clinical-pathological lectures of the SEMI] |
| Q81573531 | [Etanercept] |
| Q82719630 | [Infectious complications of biologic therapy in patients with rheumatoid arthritis] |
| Q82716875 | [Infliximab therapy in Crohn's disease complicated by Listeria monocytogenes meningoencephalitis] |
| Q79375345 | [Recommendations for the management of ankylosing spodylitis after ASAS/EULAR. Evaluation in the German language area] |
Search more.